Skip to main content
Advanced Technical IVT

thyroglobulin suppression therapy

Post-thyroidectomy treatment using levothyroxine to suppress TSH and reduce thyroglobulin levels in thyroid cancer patients.

Full Definition

Thyroglobulin suppression therapy involves administering supraphysiologic doses of levothyroxine to suppress thyroid-stimulating hormone (TSH) levels below normal ranges in patients with differentiated thyroid cancer. This treatment aims to reduce thyroglobulin production from any residual thyroid tissue and potentially inhibit tumor growth, as TSH can stimulate both normal and malignant thyroid cells. The degree of suppression is tailored to cancer risk, with high-risk patients requiring more aggressive suppression. Monitoring includes regular thyroglobulin levels, TSH measurements, and assessment for cardiovascular and bone-related side effects of prolonged thyroid hormone excess.

Usage

Usage note: Distinguish from routine hormone replacement therapy in dosing and monitoring goals.

In Context

  • "The oncology team initiated thyroglobulin suppression therapy with a target TSH of less than 0.1 mU/L following completion of radioactive iodine treatment." — oncology consultation
  • "After five years of disease-free follow-up, the patient was transitioned from thyroglobulin suppression therapy to physiologic hormone replacement." — endocrinology follow-up note

Also known as

TSH suppression therapy thyroid hormone suppression

Contrasted with

thyroid hormone replacement

Don't confuse with

radioactive iodine ablation thyroglobulin monitoring

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON